1. Market Research
  2. > Healthcare Market Trends
IV and Oral Iron Drugs Market - Global Outlook and Forecast 2021-2026

IV and Oral Iron Drugs Market - Global Outlook and Forecast 2021-2026

  • February 2021
  • 342 pages
  • ID: 5779105
  • Format: PDF
  • Arizton
Up to $1050 off Until Apr 20th 2021


Table of Contents

Search Inside

In-depth Analysis and Data-driven Insights on the Impact of COVID-19 Included in this Global IV and Oral Iron Drugs Market Report

The global IV and oral iron drugs market by revenue is expected to grow at a CAGR of 11.6% during the period 2021–2026.

The global IV and oral iron drugs market is expected to grow due to the prevalence of iron deficiency (ID). This deficiency is a highly widespread nutritional disorder, affecting around one-fourth of the global population, especially women and children. It is one of the predominant causes of anemia. Anemia accounts for around 9% of the total global disease burden. Several chronic diseases are frequently associated with iron deficiency anemia (IDA) such as chronic kidney disease (CKD), chronic heart failure, cancer, and inflammatory bowel diseases. As anemia is associated with chronic fatigue, diminished well-being, and impaired cognitive function, the treatment with oral and IV iron drugs reduces the need for blood transfusion in patients. Further, the WHO rates ID as the most common and widespread nutritional disorder globally, and its prevalence is expected to grow with the aging population and the incidence of various chronic disorders.

The following factors are likely to contribute to the growth of the IV and Oral Iron Drugs market during the forecast period:
• Strategic Collaborations & Licensing Opportunities
• Investigational Iron Drugs
• Increasing Availability of Branded Iron Therapeutics and Expanded Indication Approvals

The study considers the present scenario of the IV and Iron drugs market and its market dynamics for the period 2020?2026. It covers a detailed overview of several market growth enablers, restraints, and trends. The report offers both the demand and supply aspects of the market. It profiles and examines leading companies and other prominent ones operating in the market.

Global IV and Oral Iron Drugs Market Segmentation
The global IV and Oral iron drugs market research report includes a detailed segmentation by route of administration, application, patient group, distribution, geography. Expected launches of branded IV iron drugs in new markets and expanded indication approvals for existing commercially available brands are the key factors influencing the growth of IV iron drugs. The increased uptake of branded IV drugs in the US and European countries is also expected to contribute significantly during the forecast period. Moreover, the rise in global medicine and healthcare expenditure and high-sensitivity, accuracy, easy, and convenient access to intravenous iron dosages is likely to drive the demand for IV iron drugs over the next few years.

The growing prevalence of chronic kidney disease (CKD) and nephrological disorders across the world is increasing the application of iron drugs at a faster rate, and the trend is likely to continue during the forecast period. Across the globe, one in five men and one in four women have CKD among people above 65 years of age. Hence, a high prevalence of renal failures, particularly in developing countries such as China and India, where the number of older adults is increasing, is expected to affect market growth. Approximately 70% of patients with CKD suffer from iron deficiencies, which can aggravate renal anemia. Therefore, iron therapy with IV & oral iron drugs is an essential treatment option for CKD patients.

Adults constitute over 81% share of the global IV and oral iron drugs market. Adults dominate the market due to the high incidence and prevalence of ID and IDA in the elderly population across the globe. CKD is relatively common among adults, with a prevalence rate of up to 13%. With the increase in the incidence of diabetes and hypertension, CKD patients are likely to grow, thereby increasing the demand for iron drugs. Also, the percentage of the geriatric population is increasing at a significant rate worldwide, which is a key factor driving the growth of the segment.

Hospital pharmacies offer iron drugs with adequate discounts and rebates. Innovations in hospital pharmacy practice have led to the emergence of pharmacists working in community health services, aged care facilities, rehabilitation facilities, and general practice clinics. Such practices of hospital pharmacists are further driving the uptake of iron drugs via hospital pharmacies.

Route of Administration
• Oral
• Intravenous (IV)
• Nephrology
• Obstetrics & Gynecology (OBGYN)
• Surgery
• Gastroenterology
• Oncology
• Heart Failure (HF)
Patient Group
• Adult
• Pediatric
• Hospital Pharmacies
• Offline Retail Pharmacies
• Online Channels

Vifor Pharma and Daiichi Sankyo Company are the leading players in the global IV and oral iron drugs market. However, AMAG Pharmaceuticals, PHARMACOSMOS, Sanofi, Allergan, Akebia Therapeutics, and Shield Therapeutics are other prominent players in the market with notable shares. Vendors are competing on a wide variety of factors such as innovations, marketing strategies, and distribution channels. Global companies have a wide geographic footprint, diversified product portfolio, and a strong focus on product innovation, R&D, and business expansion activities. Key players are expected to drive sales and margin growth in their business by expanding sales organization, maintaining technology leadership through R&D, and continuing to build clinical evidence to support the benefits of the products as well as services.

Prominent Vendors
• Vifor Pharma
• Daiichi Sankyo Company

Other Prominent Vendors
• AMAG Pharmaceuticals
• Akebia Therapeutics
• Shield Therapeutics
• Allergan
• Sanofi
• AOP Orphan Pharmaceuticals

Other Vendors
• AZAD Pharma
• Ciron Drugs & Pharmaceuticals
• Pfizer
• Rockwell Medical
• Salveo Lifecare
• Sunny Pharmaceutical

The North American IV and oral iron drugs market share is expected to witness promising growth during the forecast period. The high uptake of branded iron drugs is one of the major reasons for strong growth. Vendors offering branded drugs are generating significantly higher revenue from the US than other markets. Also, the increased healthcare spending in the US and Canada is further contributing to the growth of the market. The prevalence of ID is likely to increase during the forecast period as the number of people with conditions such as CKD, CHF, IBD, and uterine bleeding is increasing in the country. Moreover, according to the United States Renal Data System (USRDS), the number of people suffering from CKD in the US alone was around 30 million people in 2020. A stressful lifestyle and the rise in chronic conditions are factors for the increase in the number of people with ID in the region.

• North America
o US
o Canada
• Europe
o UK
o Germany
o France
o Italy
o Spain
o China
o India
o Japan
o South Korea
o Australia
• Latin America
o Mexico
o Brazil
o Argentina
• Middle East & Africa
o Saudi Arabia
o Turkey
o South Africa

1. What is the IV and oral iron drugs market size and growth rate during the forecast period?
2. What is the impact of COVID-19 on the intravenous iron drugs market share?
3. Which regions are expected to observe high revenues for IV and oral drugs during the forecast period?
4. Who are the notable market players in the global IV and oral iron drugs market?
5. What are the opportunities and threats faced by key vendors in the market?

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
20% Off


  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Ahmad helps you find the right report:

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

Apheresis Market - Growth, Trends, and Forecast (2020 - 2025)

  • $ 4250
  • January 2021
  • 132 pages

The propelling factors for the growth of the apheresis market include the increasing number of diseases, a rise in the demand for blood components and associated safety, technological advancement in the ...

  • World
  • APAC
  • Healthcare
  • Blood Supply
  • Industry analysis
  • Cancer Incidence
  • Drug Approval


Reportlinker.com © Copyright 2021. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on